Finance

Lists
Why is FBIO down 5,53%?
Dive Deeper
FBIO:NASDAQ
Fortress Biotech Inc
1,88 $
-5,53%
(-0,11) 1D
13 қар., 16:00:01 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for FBIO...
Open
1,92 $
High
1,94 $
Low
1,76 $
Mkt. cap
62,70 млн
Avg. vol.
234,54 м.
Volume
310,60 м.
P/E ratio
0,71
52-wk high
4,53 $
52-wk low
1,76 $
EPS
2,65 $
Beta
1,27
Shares outstanding
33,35 млн
No. of employees
78
Open
1,92 $
High
1,94 $
Low
1,76 $
Mkt. cap
62,70 млн
Avg. vol.
234,54 м.
Volume
310,60 м.
P/E ratio
0,71
52-wk high
4,53 $
52-wk low
1,76 $
EPS
2,65 $
Beta
1,27
Shares outstanding
33,35 млн
No. of employees
78
News stories
From web sources and news partners
Profile
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida. Wikipedia
About Fortress Biotech Inc
CEOLindsay Rosenwald
Employees78
Founded2006
HeadquartersBay Harbor Islands, Флорида, Америка Құрама Штаттары
SectorHealth Care
Industry-
Analyst ratings
Based on 1 analyst giving stock ratings to FBIO in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for FBIO in the last 3 months
Highest
Current 1,88 $
5,00 $ (+165,96%)
Average
5,00 $ (+165,96%)
Lowest
5,00 $ (+165,96%)
Analyst
Recommendation
Action
Price target
Projected
Date
Scott Henry
Alliance Global Partners
Buy
Maintained
5,00 $
+166%
08/24/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
17,00 $
+804,3%
02/23/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
17,63 млн
16,08 млн
16,04 млн
18,72 млн
Cost of goods sold
5,96 млн
5,07 млн
6,76 млн
6,95 млн
Cost of revenue
5,96 млн
5,07 млн
6,76 млн
6,95 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
17,42 млн
14,73 млн
15,89 млн
20,81 млн
Operating expense
18,48 млн
15,80 млн
17,02 млн
21,78 млн
Total operating expenses
24,44 млн
20,87 млн
23,78 млн
28,72 млн
Operating income
-6,81 млн
-4,79 млн
-7,74 млн
-10,01 млн
Other non operating income
32,74 млн
5,00 мың
152,83 млн
10,74 млн
EBT including unusual items
8,85 млн
-6,21 млн
142,29 млн
922,00 м.
EBT excluding unusual items
23,93 млн
-6,19 млн
142,29 млн
840,00 м.
Income tax expense
26,00 мың
-816,00 м.
5,13 млн
320,00 м.
Effective tax rate
0,29%
13,13%
3,61%
34,71%
Other operating expenses
-
-
-
-
Net income
5,85 млн
-3,94 млн
110,37 млн
-468,00 м.
Net profit margin
33,18%
-24,49%
688,20%
-2,50%
Earnings per share
-
-
-
-
Interest and investment income
736,00 м.
637,00 м.
570,00 м.
1,58 млн
Interest expense
-2,74 млн
-2,04 млн
-3,37 млн
-1,48 млн
Net interest expenses
-2,01 млн
-1,40 млн
-2,80 млн
105,00 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,65 млн
-3,63 млн
-6,52 млн
-8,94 млн
Gain or loss from assets sale
-
-
-
-82,00 мың
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google қолданбалары